Alpha 2.0
Login Register
» Authors » Hemming Johansson

Hemming Johansson

Explore the profile of Hemming Johansson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 107
Citations 1567
Followers 0
Related Specialties
Oncology
General Surgery
Hematology
Top 10 Co-Authors
Yvonne Brandberg
Jonas Bergh
Mats Hellstrom
Mia Bergenmar
Theodoros Foukakis
Tommy Fornander
Thomas Hatschek
Lena Sharp
Sahar Salehi
Brita Arver
Published In
Acta Oncol
Breast Cancer Res Treat
Eur J Cancer
Eur J Oncol Nurs
Int J Gynecol Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial
Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, et al.
NPJ Breast Cancer . 2025 Mar; 11(1):23. PMID: 40055382
Breast cancer (BC) represents a heterogeneous ecosystem and elucidation of tumor microenvironment components remains essential. Our study aimed to depict the composition and prognostic correlates of immune infiltrate in early...
2.
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial
Matikas A, Papakonstantinou A, Loibl S, Steger G, Untch M, Johansson H, et al.
Lancet Reg Health Eur . 2024 Dec; 49:101162. PMID: 39703564
Background: It is unclear whether some patients with high-risk breast cancer do not warrant adjuvant dose-dense chemotherapy due to small expected absolute benefit. Methods: The phase 3 PANTHER trial (NCT00798070)...
3.
Effect of intraperitoneal ropivacaine during and after cytoreductive surgery on time-interval to adjuvant chemotherapy in advanced ovarian cancer: a randomised, double-blind phase III trial
Hasselgren E, Groes-Kofoed N, Falconer H, Bjorne H, Zach D, Hunde D, et al.
Br J Anaesth . 2024 Nov; 134(3):662-670. PMID: 39572271
Background: In a previous phase II trial, intraperitoneal local anaesthetics shortened the time interval between surgery and adjuvant chemotherapy, an endpoint associated with improved survival in advanced ovarian cancer. Our...
4.
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
Matikas A, Mobus V, Greil R, Andersson A, Steger G, Untch M, et al.
J Clin Oncol . 2024 Jul; 42(26):3077-3082. PMID: 39018515
JCO .Although dose-dense adjuvant chemotherapy administered once every 2 weeks leads to superior outcomes compared with standard regimens once every 3 weeks, the observed improvement is largely limited to studies...
5.
Prognostic value of bone marrow and tumor F-FDG uptake on PET/CT in patients with oropharyngeal cancer and the interplay between inflammation and FDG uptake
Christou C, Sandstrom K, Regula N, Tiblom Ehrsson Y, Johansson H, Sorensen J, et al.
Head Neck . 2024 Mar; 46(10):2422-2431. PMID: 38441400
Aims: To examine the prognostic value of F-18 fluorodeoxyglucose (FDG) uptake in the bone marrow (BM) for disease recurrence and survival in patients with oropharyngeal squamous cell carcinoma (OP-SCC). The...
6.
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Zhu Y, Zerdes I, Matikas A, Cruz I, Bergqvist M, Elinder E, et al.
Breast Cancer Res Treat . 2024 Jan; 204(2):299-308. PMID: 38175448
Background: Thymidine kinase 1 (TK1) plays a pivotal role in DNA synthesis and cellular proliferation. TK1 has been studied as a prognostic marker and as an early indicator of treatment...
7.
Comparison between Swedish EORTC QLQ-C30 general population norm data published in 2000 and 2019
Johansson H, Lagergren P, Nolte S, Brandberg Y
Acta Oncol . 2023 Oct; 62(12):1592-1598. PMID: 37862371
Background: Normative health-related quality of life (HRQoL) data from the general population are regularly used to facilitate the interpretation of HRQoL as reported by cancer patients participating in cancer clinical...
8.
Incidence of and survival after surgical intervention for bowel obstruction in women with advanced ovarian cancer
Palsdottir K, Salehi S, Johansson H, Groes-Kofoed N, Falconer H, Joneborg U
Acta Obstet Gynecol Scand . 2023 Sep; 102(12):1653-1660. PMID: 37681645
Introduction: Women with advanced ovarian cancer commonly present with peritoneal disease both at primary diagnosis and relapse, with risk of subsequent bowel obstruction. The aims of this study were to...
9.
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region
Andersson M, Johansson H, Osterborg A, Mansson-Broberg A, Hansson L, Palma M
Eur J Haematol . 2023 Aug; 111(5):748-756. PMID: 37565648
Objective: Ibrutinib treatment is associated with cardiovascular side effects, in particular atrial fibrillation (AF) and hypertension, as well as increased risk of bleeding. Here, we aimed at describing the incidence...
10.
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients
Mattsson A, Eketorp Sylvan S, Axelsson P, Ellin F, Kjellander C, Larsson K, et al.
Eur J Haematol . 2023 Jul; 111(5):715-721. PMID: 37501508
Objectives: We examined the efficacy and toxicity of the PI3Kδ inhibitor idelalisib in combination with rituximab salvage therapy in consecutively identified Swedish patients with chronic lymphocytic leukemia (CLL). Methods And...